Acetazolamide pharma grade API for immediate-release tablet compression is specified against the current USP monograph for Acetazolamide Tablets and ICH Q6A decision trees for critical quality attributes. The crystalline powder is micronized to a D90 of ≤ 20 µm because equilibrium solubility in 0.01 N HCl at 37 °C remains below 1.0 mg/mL, and dissolution failures are observed when the untreated API size fraction exceeds 75 µm. A direct compression platform for 125 mg or 250 mg dose uses a drug load of 45% to 55% w/w, microcrystalline cellulose NF at 30% to 40% w/w, lactose monohydrate at 10% to 15% w/w, croscarmellose sodium at 2.5% to 4.0% w/w, povidone K30 at 2.0% to 3.0% w/w, and magnesium stearate at 0.75% w/w. The blend is sampled at ten positions using a powder thief and assayed by HPLC; content uniformity per USP <905> must produce an acceptance value ≤ 15.0. Tablet compression on a rotary press with 10.0 mm round flat-faced beveled tooling targets hardness of 6.0 to 8.0 kp; friability per USP <1216> stays below 0.8% after 100 revolutions, and disintegration per USP <701> completes in 0.1 N HCl at 37 °C within 15 min.

Process failure modes observed on production-scale rotary presses include weight variation exceeding 3.0% RSD when the granulation is discharged with LOD above 2.0% w/w, and sticking to upper punches when compression room humidity exceeds 60% RH without excipient pre-drying. Magnesium stearate blending beyond 5 min at 12 rpm depresses the 60 min dissolution below the monograph Q value of 80% in 0.01 N HCl; therefore, lubricant contact time is capped at 5 min and the weight of lubricant is not increased above 0.75% w/w. Tablets packed in HDPE bottles with desiccant show no release shift after 6 months at 40 °C/75% RH in accelerated stability protocols derived from ICH Q1A. The finished immediate-release tablet is used for open-angle glaucoma, acute mountain sickness prophylaxis, and adjunctive therapy in certain seizure disorders, with oral dosing of 125 mg to 250 mg every 6 h to 12 h.

What Limits Uniform Content in Low-Dose Acetazolamide Granule Blends for Single-Dose Sachet Packaging?

Low-dose oral granule formulations intended for single-dose sachet reconstitution are constrained by the API agglomeration tendency and electrostatic adhesion to stainless steel blender surfaces when the drug load falls below 10% w/w. The granule composition for a 100 mg sachet uses acetazolamide at 5% to 10% w/w, mannitol at 60% to 75% w/w, sucrose at 10% to 20% w/w, citric acid and sodium citrate buffer system at 1% to 2% w/w, and xanthan gum at 0.3% to 0.5% w/w. The API is pre-blended with one-third of the mannitol for 10 min in a bin blender at 12 rpm before high-shear wet granulation; purified water is sprayed at 2% to 4% w/w binder solution rate until a wet mass end-point is reached. The wet mass is passed through a 1.0 mm screen at impeller speed 200–300 rpm and chopper speed 1500 rpm, then dried in a fluid-bed dryer with inlet air 50 °C to 60 °C to a final LOD of 1.5% to 2.0% w/w. The dried granule fraction between 150 µm and 850 µm is filled into sachets by volumetric filler; content uniformity per USP <905> requires single-sachet assay between 85.0% and 115.0% of label claim and RSD ≤ 6.0%.

Microbial quality of the sachet granule is governed by USP <61> and USP <62> for total aerobic microbial count, total yeast and mold count, and absence of specified biliary-tolerant Gram-negative organisms; water activity below 0.60 after drying suppresses microbial proliferation during storage. Dissolution of the reconstituted suspension is tested per USP <711> in 900 mL of 0.01 N HCl at 37 °C with Apparatus 2 at 50 rpm; not less than 80% of the labeled acetazolamide is released within 30 min after reconstitution. Residual solvent testing per USP <467> is applied when the granulation uses ethanol-based binder, and elemental impurities are controlled under ICH Q3D oral option. The finished granule is reconstituted by caregiver or hospital pharmacy to 25 mg/mL oral suspension immediately before use; the granule sachet is indicated for pediatric glaucoma, altitude sickness in children, and adult dysphagia where solid tablets are inappropriate.

Extended-Release Pellet Coating Requires Pore-Former Adjustment for Carbonic Anhydrase Inhibition

For 500 mg extended-release acetazolamide capsules, drug-layered pellets are manufactured on microcrystalline cellulose spheres of 600–710 µm using acetazolamide API suspended in a binder solution of povidone K30 at 5% to 8% w/w. The drug-layering process applies the suspension through a Würster column at inlet air temperature 40 °C to 50 °C and spray rate 5–10 g/min/kg of cores until a drug load of 50% to 65% w/w is achieved. A seal coat of hydroxypropyl methylcellulose at 2% w/w weight gain is applied before the functional controlled-release coat; the functional coat consists of ethylcellulose aqueous dispersion and HPMC as pore former at a ratio of 85:15, with triethyl citrate at 20% w/w of the polymer solids. Coating weight gain is maintained at 12% to 15% w/w, followed by curing at 60 °C for 2 h to coalesce the polymer film. The cured pellets are filled into hard gelatin capsules to a 500 mg dose and subjected to two-stage dissolution per USP <711>: 0.1 N HCl for the first 2 h, followed by phosphate buffer pH 6.8 for 10 h additional testing.

The critical formulation boundary is the pore-former ratio. Reducing HPMC below 10% of polymer solids produces a dense ethylcellulose film that retards release below 75% at 12 h; increasing HPMC above 20% of polymer solids creates hydrophilic channels that release more than 30% of the dose in the first 2 h acid stage, which is outside extended-release protection. Overcoating above 18% w/w similarly suppresses late-stage release, while undercoating below 8% w/w risks dose dumping if the seal coat is cracked during capsule filling. The finished extended-release capsule is used in sustained intraocular pressure reduction for chronic open-angle glaucoma and in altitude sickness prophylaxis with twice-daily dosing; the extended-release profile reduces dosing frequency compared with immediate-release tablets, though published data for this specific configuration is limited.

For the injectable presentation, acetazolamide is converted to the sodium salt by dissolution in Water for Injection at 25 °C to 30 °C, with pH adjusted to 8.5 to 9.5 using 1 M sodium hydroxide. The solution is clarified through a 0.45 µm prefilter followed by aseptic filtration through a 0.22 µm sterilizing-grade membrane; the filtrate is filled into type I glass vials at 5.0 mL per vial to deliver 500 mg acetazolamide as lyophilized powder. Lyophilization cycle parameters include freezing at -40 °C for 2 h, primary drying at -20 °C and 100 mTorr for 12 h, and secondary drying at 25 °C for 6 h to a moisture content not more than 2.0% w/w. The finished vial is a single-dose parenteral requiring reconstitution with 5.0 mL Sterile Water for Injection to a nominal 100 mg/mL concentration before slow intravenous injection.

Sterility is verified per USP <71> using membrane filtration; bacterial endotoxin testing per USP <85> is set at a limit calculated from the maximum adult dose and a threshold of 5.0 EU/kg body mass per hour. Particulate matter per USP <788> for small-volume parenterals has acceptance limits of not more than 6000 particles/container at ≥ 10 µm and not more than 600 particles/container at ≥ 25 µm. Visible particulate inspection per USP <790> is performed after reconstitution on every batch. The reconstituted solution is used for intravenous therapy of acute angle-closure glaucoma, intraoperative ocular pressure reduction, diuresis in drug-induced edema, and adjunctive treatment of status epilepticus when oral administration is not feasible; the infusion solution should not be combined with acidic diluents that lower pH below 8.0 because precipitation of the free acid can occur.

Hard Gelatin Capsule Fill Formulation and Dissolution Correlation

Hard gelatin capsule fill for immediate-release acetazolamide uses a dry blend of API at 30% to 50% w/w, lactose monohydrate NF at 40% to 55% w/w, croscarmellose sodium at 2% to 4% w/w, sodium lauryl sulfate at 0.5% to 1.0% w/w, and magnesium stearate at 0.5% to 1.0% w/w. The API is pre-blended with a quarter of the lactose for 10 min in a V-blender at 20 rpm; the remaining excipients are added and blended for 15 min, with magnesium stearate added last and blended for only 3 min to avoid hydrophobic film formation. The final blend has bulk density 0.35 to 0.50 g/mL and is filled into size 3 hard gelatin capsules for 250 mg dose or size 4 for 125 mg dose on an intermittent-motion dosator machine with pin height adjusted to achieve weight variation below 3.0% RSD. Capsule shells are conditioned to moisture content 13% to 16% w/w; relative humidity below 40% RH in the filling suite causes shell brittleness and splitting during crimping.

Dissolution of hard capsules is tested per USP <711> in 900 mL of 0.01 N HCl at 37 °C with Apparatus 2 at 50 rpm; not less than 80% is released at 60 min. Sodium lauryl sulfate in the formula acts as a wetting agent; when the surfactant level is reduced below 0.5% w/w, dissolution at 60 min falls below 75% for micronized API, and when raised above 1.0% w/w, capsule fill flow becomes inadequate. Content uniformity per USP <905> must meet acceptance value ≤ 15.0 across 10 individual capsules. The finished hard gelatin capsule is used as an alternative to tablets for glaucoma and epilepsy maintenance therapy in patients who report esophageal retention of solid tablets; no sustained-release claim is made for this dosage form.

When Acetazolamide Is Compounded into Oral Suspension Vehicle at 25 mg/mL

Extemporaneous compounding of acetazolamide oral suspension from API powder in a community or hospital pharmacy is regulated by USP <795> for nonsterile compounding and USP <800> if the compounding site classifies the sulfonamide API as a hazardous drug under its risk assessment. The 25 mg/mL suspension is prepared by levigating 500 mg of acetazolamide API or crushed tablets with a small portion of glycerin or SyrSpend SF until a smooth paste is formed; the paste is then incorporated into a 1:1 mixture of Ora-Plus and Ora-Sweet or alternative suspending vehicle to a final volume of 20 mL. The vehicle mixture is selected for pH 4.0 to 5.0 and viscosity 300 to 500 cP at 25 °C to suspend the API without excessive foaming. The compounded suspension is stored in an amber polyethylene terephthalate bottle at 4 °C and assigned a beyond-use date of 14 days based on published stability data for this specific configuration; storage at 25 °C shortens the beyond-use date to 7 days.

Dose accuracy for the compounded oral suspension depends on resuspension by shaking, because acetazolamide particles settle over 24 h to a sediment volume of 0.3 to 0.5 in the Ora-Plus:Ora-Sweet vehicle. The pharmacy preparation is dispensed with an oral syringe and dosing chart; the final product is used for pediatric glaucoma, neonatal post-hemorrhagic hydrocephalus off-label, and adult patients with nasogastric tubes requiring a liquid carbonic anhydrase inhibitor. The operational boundary is pH-dependent chemical stability: alkaline pH above 8.0 accelerates hydrolytic degradation of the sulfonamide group, while pH below 3.0 causes precipitation and caking, so the vehicle pH is not adjusted with strong bases or acids after the API is incorporated.